BOSTON, Nov. 20 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. is pleased to announce that the Company has received a purchase order for its Mammo View(TM) system. Solos Endoscopy received the order from Clarian Health Partners.
Clarian Health is an acknowledged leader in quality clinical care, education and research that offer exemplary levels of respect and dignity to patients and their families. Clarian and Indiana University School of Medicine collaborate to effectively allocate scarce resources to maximize this vision. Clarian’s cancer services earned the distinction of 44th best clinical cancer program in the United States for 2005, according to U.S. News & World Report. The Indiana University Cancer Center is a National Cancer Institute designated Cancer center. Nearly 40,000 patients turn to the IU Cancer Center for cancer care each year.
Solos Endoscopy’s Mammo View(TM) system employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts where the majority of breast cancers arise. The Mammo View(TM) system contains versatile and customizable medical equipment that can support multiple procedures including biopsies, lumpectomies, and other intraductal procedures. The Mammo View(TM) has the potential to help the early diagnosis of more than 1 million cases of breast cancer discovered each year throughout the world.
“We are honored to have our Mammo View(TM) system in such a highly recognized cancer center. The Company is excited to have Clarian join our clientele in battling breast cancer. We believe that the orders we continue to see are a testament to the quality and effectiveness of Solo’s product line,” stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos’ sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company’s website at: http://www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
CONTACT: Investor Relations for Solos Endoscopy, Inc., +1-866-THE-APPL(E)
Web site: http://www.solosendoscopy.com//
